LISOCABTAGENE MARALEUCEL VERSUS STANDARD OF CARE (SALVAGE CHEMOTHERAPY FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION) AS SECOND-LINE THERAPY IN RELAPSED/REFRACTORY LBCL: TRANSFORM RESULTS

LONG-TERM FOLLOW-UP ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL)

SUPERIORITY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN SECOND-LINE (2L) LARGE B-CELL LYMPHOMA (LBCL) IN THE ELDERLY

TWO-YEAR FOLLOW-UP OF TRANSCEND NHL 001 (TRANSCEND), A MULTICENTER PHASE 1 STUDY OF LISOCABTAGENE MARALEUCEL(LISO-CEL) IN RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMAS (LBCL)

DEVELOPMENT, SAFETY AND EFFICACY OF LOCALLY PRODUCED NOVEL BCMA CART CELLS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

PRIMARY ANALYSIS OF ZUMA‑7: A PHASE 3 RANDOMIZED TRIAL OF AXICABTAGENE CILOLEUCEL(AXI-CEL) VERSUS STANDARD‑OF‑CARE(SOC) THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

HAPLO OR UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS: A RANDOMIZED MULTICENTER PHASE III STUDY.

MEASURABLE-RESIDUAL DISEASE GUIDED TREATMENT WITH AZACITIDINE IN MDS/AML PATIENTS AT IMMINENT RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF THE PROSPECTIVE RELAZA2 TRIAL

PREDICTORS OF LONG TERM RESPONSE WITH CD28-BASED CD19 CAR T-CELLS IN CHILDREN AND YOUNG ADULTS WITH B-ALL

PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): 1-YEAR FOLLOW-UP OF ZUMA-1 COHORT 6 (C6)

TREATMENT OF ADULT ALL PATIENTS WITH THIRD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS - RESULTS OF THE HEIDELBERG TRIAL 1 (HD-CAR-1 TRIAL)

TABELECLEUCEL FOR EPSTEIN–BARR VIRUS-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL (HCT) OR SOLID ORGAN TRANSPLANT (SOT) AFTER FAILURE OF RITUXIMAB +/- CHEMOTHERAPY (ALLELE)

POST-REMISSION TREATMENT PATTERN AND SURVIVAL OUTCOMES IN CONNECT® MYELOID DISEASE REGISTRY PATIENTS WITH ACUTE MYELOID LEUKEMIA

COMBINATION OF RUXOLITINIB AND INTERFERON Α-2B IS EFFECTIVE FOR TREATMENT OF RELAPSE OR MINIMAL RESIDUAL DISEASE AFTER ALLO-SCT: PHASE I/II STUDY OF NCT02185261 AND NCT02568241

PROSPECTIVE PHASE II STUDY OF PREEMPTIVE CHIMERISM-DRIVEN REDUCTION OF IMMUNOSUPPRESSION AFTER NON-MYELOABLATIVE CONDITIONING — SUBANALYSIS OF PATIENTS WITH MYELOID NEOPLASMS - EUDRACT #: 2007-002420-15